Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Taisho, Takeda to Wind Up Japan Distribution Deal for Biofermin’s Prescription Drugs
September 2, 2020
- Fujifilm Files Radiopharmaceutical Drug F-1515 in Japan
September 1, 2020
- Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
September 1, 2020
- Sanofi’s Sarclisa Hits Japan Market, Zeria Launches Ferinject
September 1, 2020
- Edoxaban Hits PIII Goal in Very Elderly Patients: Daiichi Sankyo
September 1, 2020
- Sales Rep Promotions Up in July, but Online Channels Down: Intage
August 31, 2020
- Shionogi Pharma Files Baktar Small-Sized Tablets to Improve Compliance in Children
August 31, 2020
- Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
- MEDRx/D. Western Therapeutics’ Lidocaine Tape Formulation Filed for Post-Herpetic Neuralgia in US
August 28, 2020
- 2 More HIF-PH Inhibitors, Enerzair, Enspryng and More Now Available in Japan
August 27, 2020
- JCR to Commence Full-Fledged Biz for Lysosomal Storage Disorder Meds in Brazil
August 27, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Thailand
August 27, 2020
- As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster
August 26, 2020
- Carna Bio Starts First-in-Human Trial for BTK Inhibitor
August 26, 2020
- Sanwa Kagaku Files SHPT Med for Japan Approval
August 26, 2020
- Drug Makers Taking Mixed Disclosure Policies for Coronavirus Infections
August 25, 2020
- Takeda to Sell Japan OTC Biz to Blackstone, Weber Says It’s the Right Choice
August 25, 2020
- Takeda to Offload Japan OTC Biz to Blackstone for 242 Billion Yen
August 24, 2020
- Japan Drug Makers’ Q1 Profit Surges on Voluntary Bans on Doctor Calls: Jiho Tally
August 24, 2020
- Japan Approves CureApp’s Smoking Cessation Apps
August 24, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…